Eli Lilly and Company

Tianwei Ma

Ying Kwong Yee

Sunil Nagpal

Jianliang Lu

Charles David Jones

Robert Peter Gajewski

Alan M Warshawsky

Ryan Edward Stites

Jason Matthew Ochoada

Michael Gregory Bell

Peter Ambrose Lander

Lindsay Stelzer

Michael James Genin

Lian Zhu Liu

Robert Anthony Doti

Emilio Enrique Bunel

Zhi Long Hu

Liang Wu

Nathan Bryan Mantlo

Jingye Zhou

Xuejun Zhang

Haizhen Zhang

Quanrong Shen

Peter Rudolph Manninen

Jared Harris Linebarger

Mi Zeng

Ana Belen Bueno Melendo

Lance Allen Pfeifer

Douglas Linn Gernert

Francisco Javier Agejas-Chicharro

Ashraf Saeed

Fucheng Qu

Karl Robert Dahnke

Antonio Navarro

Todd Parker Simard

Matthew Scott Dowling

Zhilong Hu

Lianzhu Liu

Mi Emily Zeng

Lindsay Scott Stelzer

The present invention provides a compound of formula or a pharmaceutical salt thereof, use, methods for its preparation are described.

Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds

The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described. 

A compound of the Formula (1) is below provided where R1-R5 are as described in the description and each '*' represents a chiral center. 

Cyclohexyl benzamide compounds

The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds.

Tetrahydropyranyl benzamide derivatives

The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH, CH(CH), CHCN, CHCHF, CHCF, (A), (B), (C), (D), (E), (F), CHCHOCH, and CHC(O)OCH(CH); Ris selected from the group consisting of CF, OCF, and Cl; Ris selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof. 

GPR142 agonist compounds

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds and methods for modulating FXR

Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds and methods for modulating FX-receptors

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

FXR agonists

The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Vitamin D receptor modulators

The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Phenyl-thiophene type vitamin D receptor modulators

The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C-Calkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.

Triazole PPAR modulators

The present invention relates to novel, non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Growing community of inventors

Carmel, IN, United States of America

Tianwei Ma